New Horizons in Relapsed/Refractory Multiple Myeloma: Improving Outcomes With Novel Immunotherapies

Despite the availability of many therapeutic options to treat multiple myeloma (MM), the disease progresses, and patients ultimately become refractory to specific agents or drug classes. Treatment selection and sequencing can be extremely challenging for clinicians. Fortunately, newer approaches to the treatment of relapsed/refractory MM have been developed, particularly with the advent of approved and upcoming of chimeric antigen receptor T-cell therapies and bispecific antibodies. These discussions highlight the emerging and available agents that are critical to the evolving therapeutic landscape of MM.